Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 20 of 40

Benefits of Medications (1 of 2)

For postmenopausal women with osteoporosis, the following medications reduce the risk of the listed fracture types. The strength of evidence, high, moderate, or low, is listed for each.

The bisphosphonates are alendronate, risedronate, zoledronic acid, and ibandronate. Alendronate and risedronate each reduce the risk of vertebral, nonvertebral, hip, and wrist fractures. The strength of evidence is high for evidence about vertebral and hip and other nonvertebral fractures. The strength of evidence is low for wrist fracture prevention by risedronate and alendronate, and in the case of risedronate, the evidence for reduced risk of wrist fractures did not reach the conventional level of statistical significance. Zoledronic acid reduces the risk of vertebral, nonvertebral, and hip fractures. The strength of evidence in support of these findings is high. The effect of zoledronic acid on wrist fracture risk was not specified. Ibandronate reduces the risk of vertebral fractures, and the strength of the evidence in support of the finding is high. The effect of ibandronate on nonvertebral, hip, and wrist fractures was not specified.

Denosumab reduces the risk of vertebral, hip, and other nonvertebral fractures. The strength of evidence in support of these findings is high. The effect of denosumab on risk of wrist fractures was not specified.

Teriparatide reduces the risk of vertebral and nonvertebral fractures. The strength of evidence for prevention of vertebral fractures is high, and for nonvertebral fractures the strength of evidence for the finding is moderate. The effect of teriparatide on hip and wrist fracture risk was not specified.

Raloxefine reduces the risk of vertebral fractures, and this finding is supported by high strength of evidence. Raloxifene does not reduce the risk for nonvertebral, hip, or wrist fractures, and the evidence in support of these conclusions is high.